Kiora Pharmaceuticals (KPRX)
NASDAQ:KPRX
Want to see KPRX full AI Analyst Report?
KPRX Stock Chart & Stats
$1.91
-$0.13(-3.22%)
At close: 4:00 PM EST
$1.91
-$0.13(-3.22%)
Day’s Range― - ―
52-Week Range$1.76 - $3.29
Previous CloseN/A
Volume13.46K
Average Volume (3M)36.18K
Market Cap
$11.52M
Enterprise Value$1.30M
Total Cash (Recent Filing)$13.87M
Total Debt (Recent Filing)$373.59K
Price to Earnings (P/E)―
Beta1.24
Next Earnings
Aug 07, 2026EPS Estimate
-0.47Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.66
Shares Outstanding4,431,940
10 Day Avg. Volume38,148
30 Day Avg. Volume36,176
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.51
Price to Sales (P/S)0.00
P/FCF Ratio-0.81
Enterprise Value/Market Cap0.11
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-16.15
Enterprise Value/Ebitda-0.10
Forecast
1Y Price Target
$12.00Price Target Upside528.27% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-2.89
Revenue Forecast (FY)$1.50M
Bulls Say, Bears Say
Bulls Say
Low LeverageMinimal debt (TTM debt-to-equity ~0.03) materially reduces solvency and interest burden, preserving financial flexibility. This structural strength limits bankruptcy risk and leaves capacity to access capital markets to fund clinical programs over the next several quarters.
Secured Near-Term FundingThe April 2026 private placement delivered $5M in upfront proceeds and potential incremental capital via milestone/exercise-linked warrants. That funding provides durable runway to continue R&D and trial enrollment, reducing immediate liquidity pressure while programs advance.
Focused Ophthalmic PipelineKiora's concentrated focus on retinal and ophthalmic therapies is a durable strategic asset: ongoing Phase 2 programs and a CRO-supported enrollment model enable capital-efficient trial execution, maintaining program continuity even amid management turnover.
Bears Say
Zero Revenue & Cash BurnThe company returned to zero revenue with substantial TTM losses and negative operating cash flow, meaning losses are translating to real cash burn. Persistent negative cash generation forces repeated capital raises, raising execution risk for multi-year clinical programs.
Eroding Capital BaseDeclining equity and assets indicate the balance sheet buffer is shrinking as losses continue. A reduced capital base limits the company's ability to self-fund trials, increases reliance on external financing, and raises the probability of dilutive raises during critical development milestones.
Dilution & Incentive OverhangShareholder approval of 1.5M additional incentive shares and issuance of multi-tranche warrants create meaningful dilution risk and potential share overhang. Ongoing exercises or further equity issuance to fund trials could materially dilute existing investors and complicate capital planning.
Kiora Pharmaceuticals News
KPRX FAQ
What was Kiora Pharmaceuticals’s price range in the past 12 months?
Kiora Pharmaceuticals lowest stock price was $1.76 and its highest was $3.29 in the past 12 months.
What is Kiora Pharmaceuticals’s market cap?
Kiora Pharmaceuticals’s market cap is $11.52M.
When is Kiora Pharmaceuticals’s upcoming earnings report date?
Kiora Pharmaceuticals’s upcoming earnings report date is Aug 07, 2026 which is in 55 days.
How were Kiora Pharmaceuticals’s earnings last quarter?
Kiora Pharmaceuticals released its earnings results on May 08, 2026. The company reported -$0.58 earnings per share for the quarter, beating the consensus estimate of -$0.71 by $0.13.
Is Kiora Pharmaceuticals overvalued?
According to Wall Street analysts Kiora Pharmaceuticals’s price is currently Undervalued.
Does Kiora Pharmaceuticals pay dividends?
Kiora Pharmaceuticals does not currently pay dividends.
What is Kiora Pharmaceuticals’s EPS estimate?
Kiora Pharmaceuticals’s EPS estimate is -0.47.
How many shares outstanding does Kiora Pharmaceuticals have?
Kiora Pharmaceuticals has 4,431,940 shares outstanding.
What happened to Kiora Pharmaceuticals’s price movement after its last earnings report?
Kiora Pharmaceuticals reported an EPS of -$0.58 in its last earnings report, beating expectations of -$0.71. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Kiora Pharmaceuticals?
Currently, no hedge funds are holding shares in KPRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Kiora Pharmaceuticals
Kiora Pharmaceuticals, Inc., a specialty pharmaceutical firm operating at the clinical stage, is dedicated to the creation and commercialization of treatments for various ophthalmic conditions across the United States. Its flagship therapeutic candidate, KIO-301, is a groundbreaking small molecule undergoing Phase 1 clinical trials. This innovative "photoswitch" aims to revitalize vision in individuals suffering from both inherited and age-related forms of retinal degeneration. The company's pipeline also includes KIO-101, an eye drop currently in Phase 2 trials for addressing the ocular manifestations of rheumatoid arthritis, as well as non-infectious posterior uveitis. Furthermore, Kiora is advancing KIO-201, another eye drop, which is in Phase 3 clinical trials, designed to facilitate corneal wound healing following PRK surgery. Established in 1998, the company adopted its current name in November 2021, having previously operated as Eyegate Pharmaceuticals, Inc. Kiora Pharmaceuticals maintains its corporate headquarters in Salt Lake City, Utah.
KPRX Stock 12 Month Forecast
Average Price Target
$12.00
▲(528.27% Upside)
Technical Analysis
Genprex
―
Dogwood Therapeutics
―
Sensei Biotherapeutics
―
TransCode Therapeutics
―
AEON Biopharma
―
Ownership Overview
2.69% Insiders
1.05% Mutual Funds
4.02% Other Institutional Investors
91.68% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---